Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Label-free cell signaling pathway deconvolution of angiotensin type 1 receptor reveals time-resolved G-protein activity and distinct AngII and AngIIIIV responses.

Lavenus S, Simard É, Besserer-Offroy É, Froehlich U, Leduc R, Grandbois M.

Pharmacol Res. 2018 Oct;136:108-120. doi: 10.1016/j.phrs.2018.06.027. Epub 2018 Jun 28.

PMID:
29959993
2.

The signaling signature of the neurotensin type 1 receptor with endogenous ligands.

Besserer-Offroy É, Brouillette RL, Lavenus S, Froehlich U, Brumwell A, Murza A, Longpré JM, Marsault É, Grandbois M, Sarret P, Leduc R.

Eur J Pharmacol. 2017 Jun 15;805:1-13. doi: 10.1016/j.ejphar.2017.03.046. Epub 2017 Mar 22.

PMID:
28341345
3.

iRAGE as a novel carboxymethylated peptide that prevents advanced glycation end product-induced apoptosis and endoplasmic reticulum stress in vascular smooth muscle cells.

Maltais JS, Simard E, Froehlich U, Denault JB, Gendron L, Grandbois M.

Pharmacol Res. 2016 Feb;104:176-85. doi: 10.1016/j.phrs.2015.12.015. Epub 2015 Dec 17.

PMID:
26707030
4.

Using carboxyfluorescein diacetate succinimidyl ester to monitor intracellular protein glycation.

Boucher J, Simard É, Froehlich U, D'Orléans-Juste P, Grandbois M.

Anal Biochem. 2015 Jun 1;478:73-81. doi: 10.1016/j.ab.2015.03.017. Epub 2015 Mar 21.

PMID:
25800564
5.

Amplification of AngII-dependent cell contraction by glyoxal: implication of cell mechanical properties and actomyosin activity.

Boucher J, Simard E, Froehlich U, Grandbois M.

Integr Biol (Camb). 2014 Apr;6(4):411-21. doi: 10.1039/c3ib40243f. Epub 2014 Feb 7.

PMID:
24503653
6.

Cancer-associated regulation of alternative splicing.

Venables JP, Klinck R, Koh C, Gervais-Bird J, Bramard A, Inkel L, Durand M, Couture S, Froehlich U, Lapointe E, Lucier JF, Thibault P, Rancourt C, Tremblay K, Prinos P, Chabot B, Elela SA.

Nat Struct Mol Biol. 2009 Jun;16(6):670-6. doi: 10.1038/nsmb.1608. Epub 2009 May 17.

PMID:
19448617
7.

Identification of alternative splicing markers for breast cancer.

Venables JP, Klinck R, Bramard A, Inkel L, Dufresne-Martin G, Koh C, Gervais-Bird J, Lapointe E, Froehlich U, Durand M, Gendron D, Brosseau JP, Thibault P, Lucier JF, Tremblay K, Prinos P, Wellinger RJ, Chabot B, Rancourt C, Elela SA.

Cancer Res. 2008 Nov 15;68(22):9525-31. doi: 10.1158/0008-5472.CAN-08-1769.

8.

Multiple and specific mRNA processing targets for the major human hnRNP proteins.

Venables JP, Koh CS, Froehlich U, Lapointe E, Couture S, Inkel L, Bramard A, Paquet ER, Watier V, Durand M, Lucier JF, Gervais-Bird J, Tremblay K, Prinos P, Klinck R, Elela SA, Chabot B.

Mol Cell Biol. 2008 Oct;28(19):6033-43. doi: 10.1128/MCB.00726-08. Epub 2008 Jul 21.

9.

Anticancer drugs affect the alternative splicing of Bcl-x and other human apoptotic genes.

Shkreta L, Froehlich U, Paquet ER, Toutant J, Elela SA, Chabot B.

Mol Cancer Ther. 2008 Jun;7(6):1398-409. doi: 10.1158/1535-7163.MCT-08-0192.

10.

Sex differences of hypothalamic prolactin cells develop independently of the presence of sex steroids.

Beyer C, Kolbinger W, Froehlich U, Pilgrim C, Reisert I.

Brain Res. 1992 Oct 16;593(2):253-6.

PMID:
1450932

Supplemental Content

Loading ...
Support Center